CCG-100602

Research use only, not for human use.

CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 μM).

CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 μM).

Cell Viability AssayCell Line:Human adipose stem cell (hASC) Concentration:3, 8, 15, or 30?μM Incubation Time:7 days Result:The number of adherent cells decreased as a response to increasing inhibitor amount. The effect was also dependent on the culture media because the osteogenic medium condition supported the viability over basic culture medium and adipogenic medium conditions.RT-PCR Cell Line:Human intestinal myofibroblasts (HIMFs)Concentration:5, 10, 20, and 40?μM Incubation Time:30?min prior to the addition of TGF-β1 (5?ng/mL) for 24 hours Result:Diminished the TGF-β1-induced increase in COL1A1, FN1, and ACTA2 transcription in a dose-dependent manner. Reduced the TGF-β1-induced increase in MRTFA and SRF mRNA expression in the HIMFs in a dose-dependent manner.Western Blot Analysis Cell Line:Human intestinal myofibroblasts (HIMFs)Concentration:5, 10, 20, and 40?μM Incubation Time:30?min prior to the addition of TGF-β1 (5?ng/mL) for 48 hours Result:The protein expression levels of the ECM and α-SMA in TGF-β1-stimulated cells are significantly reduced.

Animal Model:Adult (4 month-old) male spontaneously hypertensive rats (SHR) and normotensive control Wistar-Kyoto (WKY) rats Dosage:7.5 mg/kg/day Administration:Continuously administered for 2 weeks by osmotic minipumps.Result:Abrogated the increase of aortic stiffness represented by reduced arterial compliance and strain.

——

Cell Cycle/DNA Damage

Rho

rho

——

——

1207113-88-9

478.82

C21H17ClF6N2O2

>98% (HPLC)

DMSO:100 mg/mL (208.85 mM; Need ultrasonic)

ClC1=CC=C(NC(C2CN(C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)=O)CCC2)=O)C=C1

——

(-20℃)

With Ice Pack

≥ 2 years